Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F. Von Recklinhausen.
Die fibrose oder deformiedere ostitis, die steomalazie und die osteoplastische karzinose in ihren gegenseitigen beziehungen, pp. 1
[2.]
E. Murphy, G.R. Williams.
The thyroid and the skeleton.
Clin Endocrinol (Oxf), 61 (1998), pp. 285-298
[3.]
P.J. O'Shea, G.R. Wiliams.
Insight into the physiological actions of thyroid hormone receptors from genetically modified mice.
J Endocrinol, 175 (2002), pp. 553-570
[4.]
P. Vestergaard, L. Mosekilde.
Hyperthyroidism, bone mineral density and fracture risk – a meta-analysis.
Thyroid, 13 (2003), pp. 585-593
[5.]
J. Faber, A.M. Galloe.
Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
Eur J Endocrinol, 130 (1994), pp. 350-356
[6.]
B. Uzzan, J. Campos, M. Cucherat, P. Nony, J.P. Boissel, G.Y. Perret.
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab, 81 (1996), pp. 4278-4289
[7.]
S.L. Greenspan, F.S. Greenspan.
The effect of thyroid hormone on skeletal integrity.
Ann Int Med, 130 (1999), pp. 750-758
[8.]
K.A. Heemstra, N.A. Hamdy, J.A. Romjin, J.W. Smit.
The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Thyroid, 16 (2006), pp. 583-591
[9.]
M.T. McDermott, J.J. Perloff, G.S. Kidd.
A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.
Calcif Tissue Intl, 56 (1995), pp. 521-525
[10.]
C.G. Muller, T.A. Bayley, J.E. Harrison, R. Tsang.
Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.
Thyroid, 5 (1995), pp. 81-87
[11.]
H.N. Rosen, A.C. Moses, J. Garber, D.S. Ross, S.L. Lee, L. Ferguson, et al.
Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.
J Clin Endocrinol Metab, 83 (1998), pp. 2324-2330
[12.]
E. Jodar, M. Begona Lopez, L. Garcia, D. Rigopoulou, G. Martinez, F. Hawkins.
Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Osteoporos Int, 8 (1998), pp. 311-316
[13.]
G. Pioli, M. Pedrazzoni, E. Palummeri, M. Sianesi, R. Del Frate, P.P. Vescovi, et al.
Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women.
Acta Endocrinol (Copenh), 126 (1992), pp. 238-242
[14.]
A.W. Kung, T. Lorentz, S.C. Tam.
Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Clin Endocrinol (Oxf), 39 (1993), pp. 535-540
[15.]
C.Y. Guo, A.P. Weetman, R. Eastell.
Longitudinal changes in bone mineral density and bone turnover in postmenopausal women on thyroxine.
Clin Endocrinol (Oxf), 46 (1997), pp. 301-307
[16.]
T. Diamon, L. Nery, I. Hales.
A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
J Clin Endocrinol Metab, 72 (1991), pp. 1184-1188
[17.]
J.A. Franklyn, J. Betteridge, J. Daykin, R. Holder, G.D. Oates, J.V. Parle, et al.
Long-term thyroxine treatment and bone mineral density.
Lancet, 340 (1992), pp. 9-13
[18.]
C.M. Florkowski, B.E. Brownlie, J.R. Elliot, E.M. Ayling, J.G. Turner.
Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
N Z Med J, 27 (1993), pp. 443-444
[19.]
S. Giannini, M. Nobile, L. Sartori, P. Binotto, M. Ciuffreda, G. Gemo, et al.
Bone density and mineral metabolism in thyroidectomized patients treated with long term L-thyroxine.
Clin Sci, 87 (1994), pp. 593-597
[20.]
G. Görres, A. Kaim, A. Otte, M. Götze, J. Muller-Brand.
Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Eur J Nuc Med, 23 (1996), pp. 690-692
[21.]
C.H. Chen, J.F. Chen, B.Y. Yang, R.T. Liu, S.C. Tung, W.Y. Chien, et al.
Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
J Formos Med Assoc, 103 (2004), pp. 442-447
[22.]
J.L. Reverter, S. Holgado, N. Alonso, I. Salinas, M.L. Granada, A. Sanmartí.
Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Endocr Relat Cancer, 12 (2005), pp. 973-981
[23.]
C. Marcocci, F. Golia, G. Bruno-Bossio, E. Vignali, A. Pinchera.
Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
J Clin Endocrinol Metab, 78 (1994), pp. 818-823
[24.]
T.L. Paul, J. Kerrigan, A.M. Kelly, L.E. Braverman, D.T. Baran.
Longterm L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
JAMA, 259 (1988), pp. 3137-3141
[25.]
B. Larijani, F. Gharibdoost, M. Pajouhi, A. Sadjadi, S. Aghakhani, R. Eshraghian, et al.
Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
J Clin Pharm Ther, 29 (2004), pp. 1-5
[26.]
C. Ribot, F. Tremollieres, J.M. Pouilles, J.P. Louvet.
Bone mineral density and thyroid hormone therapy.
Clin Endocrinol (Oxf), 33 (1990), pp. 143-153
[27.]
A.W. Kung, S.S. Yeung.
Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
J Clin Endocrinol Metab, 81 (1996), pp. 1232-1236
[28.]
F. Hawkins, D. Rigopoulou, K. Papapietro, M.B. Lopez.
Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Calcif Tissue Int, 54 (1994), pp. 16-19
[29.]
M.I. Surks, E. Ortiz, G.H. Daniels.
Subclinical thryoid disease: scientific review and guidelines for diagnosis and management.
JAMA, 291 (2004), pp. 228-238
[30.]
I. Karner, Z. Hrgovic, S. Sijanovic, D. Bukovic, A. Klobucar, K.H. Usadel, et al.
Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Eur J Med Res, 16 (2005), pp. 480-488
[31.]
P. Mikosch, B. Obermayer-Pietsch, R. Jost, B. Jauk, H.J. Gallowitsch, E. Kresnik, et al.
Bone metabolism in patients with differentiated hyroid carcinoma receiving suppressive levothyroxine treatment.
Thyroid, 13 (2003), pp. 347-356
[32.]
F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga.
European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.
Eur J Endocrinol, 154 (2006), pp. 787-803
[33.]
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, et al.
Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Taskforce.
Thyroid, 16 (2006), pp. 109-142
[34.]
F. Sánchez-Franco.
Directrices para el tratamiento del carcinoma diferenciado de tiroides.
Endocrinol Nutr, 52 (2005), pp. 23-31
[35.]
J.M. Gómez, F. Sánchez-Franco.
Consideraciones acerca del consenso europeo para el tratamiento del cáncer diferenciado de tiroides.
Endocrinol Nutr, 53 (2006), pp. 427-429
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
